{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Biomedical+Advanced+Research+and+Development+Authority",
    "query": {
      "sponsor": "Biomedical Advanced Research and Development Authority"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 108,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Biomedical+Advanced+Research+and+Development+Authority&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T02:15:01.433Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03564158",
      "title": "Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "meropenem-vaborbactam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 53,
      "start_date": "2018-05-01",
      "completion_date": "2018-11-19",
      "has_results": false,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-09-27T02:15:01.433Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03564158"
    },
    {
      "nct_id": "NCT06560151",
      "title": "Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "3.75 µg H5N8 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N8 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N8 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.75 µg H5N8 antigen plus half dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N8 antigen plus half dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N8 antigen plus half dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.75 µg H5N8 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N8 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N8 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.75 µg H5N1 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N1 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N1 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.75 µg H5N1 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N1 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N1 antigen plus MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1380,
      "start_date": "2024-08-21",
      "completion_date": "2025-06-11",
      "has_results": true,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-09-27T02:15:01.433Z",
      "location_count": 20,
      "location_summary": "Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06560151"
    },
    {
      "nct_id": "NCT06547554",
      "title": "A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "Xeruborbactam",
          "type": "DRUG"
        },
        {
          "name": "Cefiderocol",
          "type": "DRUG"
        },
        {
          "name": "Xeruborbactam/Cefiderocol",
          "type": "DRUG"
        },
        {
          "name": "Dextrose 5% in water",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Qpex Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-09-04",
      "completion_date": "2025-10-27",
      "has_results": false,
      "last_update_posted_date": "2025-11-28",
      "last_synced_at": "2026-09-27T02:15:01.433Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06547554"
    },
    {
      "nct_id": "NCT03699124",
      "title": "Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "FD MVA-BN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 1129,
      "start_date": "2019-06-19",
      "completion_date": "2020-06-22",
      "has_results": true,
      "last_update_posted_date": "2021-05-27",
      "last_synced_at": "2026-09-27T02:15:01.433Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Melbourne, Florida • Peoria, Illinois + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03699124"
    },
    {
      "nct_id": "NCT05252910",
      "title": "Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Pharm-Olam, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2022-01-01",
      "completion_date": "2022-03-04",
      "has_results": false,
      "last_update_posted_date": "2022-04-05",
      "last_synced_at": "2026-09-27T02:15:01.433Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Omaha, Nebraska • Syracuse, New York + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Brownsville",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05252910"
    },
    {
      "nct_id": "NCT06701656",
      "title": "JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Respiratory Distress Syndrome (ARDS)",
        "ARDS",
        "ARDS (Acute Respiratory Distress Syndrome)",
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "Cohort C: bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Cohort C: placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PPD Development, LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-10-28",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-09-27T02:15:01.433Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06701656"
    },
    {
      "nct_id": "NCT05194358",
      "title": "Study of SIAN Nasal Spray in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cyanide Poisoning"
      ],
      "interventions": [
        {
          "name": "Stabilized Isoamyl Nitrite (SIAN)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 47,
      "start_date": "2021-12-21",
      "completion_date": "2023-10-13",
      "has_results": false,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-09-27T02:15:01.433Z",
      "location_count": 2,
      "location_summary": "Knoxville, Tennessee • Austin, Texas",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05194358"
    },
    {
      "nct_id": "NCT02839330",
      "title": "A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Avian Influenza"
      ],
      "interventions": [
        {
          "name": "aH5N1c",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3196,
      "start_date": "2016-07-11",
      "completion_date": "2017-10-04",
      "has_results": true,
      "last_update_posted_date": "2024-12-06",
      "last_synced_at": "2026-09-27T02:15:01.433Z",
      "location_count": 26,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02839330"
    },
    {
      "nct_id": "NCT05875961",
      "title": "Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza, Human",
        "Infections",
        "Respiratory Tract Infections",
        "Virus Diseases",
        "Infection Viral"
      ],
      "interventions": [
        {
          "name": "Low dose A/H2N3c + standard dose MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intermediate dose A/H2N3c + standard dose MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose A/H2N3c + standard dose MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose A/H2N3c non-adjuvanted",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lowest dose A/H2N3c + high dose MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low dose A/H2N3c + high dose MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2023-06-15",
      "completion_date": "2024-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-09-27T02:15:01.433Z",
      "location_count": 3,
      "location_summary": "Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05875961"
    },
    {
      "nct_id": "NCT03137173",
      "title": "Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Bacterial Skin and Skin Structure Infections"
      ],
      "interventions": [
        {
          "name": "ceftobiprole medocaril",
          "type": "DRUG"
        },
        {
          "name": "vancomycin+aztreonam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 679,
      "start_date": "2018-02-19",
      "completion_date": "2019-04-22",
      "has_results": true,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-09-27T02:15:01.433Z",
      "location_count": 16,
      "location_summary": "Anaheim, California • Chula Vista, California • Fresno, California + 10 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03137173"
    }
  ]
}